NCT01449513 2025-03-07
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
LEO Pharma
Phase 1 Completed
Clinical Trials
9 trialsNCT01387711 2025-02-24
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology
LEO Pharma
Phase 1 Completed
NCT02124239 2025-02-24
Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions
LEO Pharma
Phase 1 Completed
NCT02748902 2017-07-17
Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.
TCR Medical Corporation
Phase 1 Completed
NCT00546611 2016-01-28
The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)
Peplin
Phase 1 Withdrawn
NCT00850681 2015-09-09
A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers
Peplin
Phase 1 Completed
NCT00850811 2015-09-09
A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers
Peplin
Phase 1 Completed
NCT00544258 2015-02-12
Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005
Peplin
Phase 1 Completed
NCT01836367 2013-12-31
Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp
Icahn School of Medicine at Mount Sinai
Phase 1 Completed